
FIELD NOTE / OPEN FEASIBILITY CASE
· Updated
Norway Wants to Lead Clinical Research. Here Is One Test.
I survived heroin addiction. Now I have contacted a drug developer, assembled the documentation and put a concrete research proposal on the table. Norway has promised to strengthen clinical research. Who takes the next step?
I do not just want to tell the story of how I got out. I want to investigate what Norway is doing to give more people a way out.
In early October 2026, I reached six months without opioids, after years of heroin addiction. For me, recovery is not just about stopping a substance. It is about rebuilding the ability to choose, act and live a life that is more than survival.
That experience is why I began asking what happens when someone takes Norway's research ambitions seriously enough to bring forward a specific proposal. Not another appeal for sympathy. A question that can be investigated, challenged and answered.
Does Norway's investment in better addiction treatment match the lives being lost — and who takes responsibility when concrete research opportunities are put on the table?
The promise is public. So is the need.
The government's 2026–2036 clinical-research plan sets a measurable ambition: a place among Europe's top three countries for clinical studies per million inhabitants. It also calls for more patients in research, stronger industry collaboration and more efficient study delivery. [1]
Meanwhile, the government's own substance-use reform report describes substantial undertreatment, particularly of alcohol use disorder. It cites a 2022 estimate of NOK 80–100 billion in annual societal costs associated with alcohol use, largely reflecting lost health and quality of life rather than direct public expenditure. [2]
The Norwegian Institute of Public Health's report for 2024 records 419 alcohol-induced deaths. This is a defined cause-of-death category, not a count of every death to which alcohol contributes. [3]
A life does not become less valuable because its loss was foreseeable.
I want the research priorities examined: how much goes into developing and testing better addiction treatment, how is that effort assessed against the burden of illness, and who follows up the results? A research ambition should be traceable to decisions, resources and outcomes.
I have done more than ask the question.
I contacted Deborah Mash at DemeRx directly. In our email exchange in April 2026, she explained that alcohol trials in Norway had been discussed. Financing and navigating the Norwegian system were central obstacles.
I then assembled a preliminary Norwegian pathway: a developer willing to proceed, a qualified investigator and study site, a feasibility assessment, and a clear account of the information, resources and financing that would be needed.
On 4 October 2026, I sent an initial procedural inquiry to NorTrials about a possible Norwegian pathway for DMX-1001 in alcohol use disorder. NorTrials already provides an entry point connecting industry with Norwegian clinical-trial environments. [7]
This article makes that groundwork public. The next task is to establish whether it can support a credible study pathway. The correspondence is a starting point for that assessment, not an agreement to run a trial.
The promise has been made. A specific proposal has been put forward. I am asking for the work that connects the two: a qualified assessment and a named next step.
One candidate. An answer we do not yet have.
DemeRx is developing DMX-1001, oral noribogaine, for alcohol use disorder (AUD). My personal background is heroin addiction; this specific clinical-development proposal concerns alcohol use disorder. [4]
In January 2026, DemeRx reported completion of a Phase 1 multiple-ascending-dose trial in 55 healthy volunteers. In April, it reported that the U.S. FDA had accepted its Investigational New Drug application for AUD. Those are development milestones, not proof of clinical benefit in people with AUD. [5][6]
The questions are concrete: can the treatment improve outcomes for people with AUD, how durable would any benefit be, and do the benefits outweigh the risks? A Norwegian investigator would also need the full safety information and a defensible rationale for the proposed study.
My request is to assess a route to reliable answers. Not to settle the efficacy question with either my experience or the developer's expectations.
Who takes the next step?
I am asking for one bounded first assessment: is a Norwegian study pathway worth pursuing, what is missing, and who is the appropriate person to carry the next action?
That requires an up-to-date development brief from DemeRx, a critical assessment from a relevant Norwegian clinical team, and guidance on the appropriate feasibility process. NorTrials is an existing route for connecting industry with potential investigators. [7]
The practical questions should be explicit:
- Does the proposed study have a credible clinical rationale, relevant safety evidence and outcomes that matter to people with AUD?
- Is there an interested Norwegian investigator and site with the population, recruitment capacity and resources the protocol requires?
- Can investigational-product handling, pharmacy support, monitoring and the necessary regulatory and ethics reviews be arranged?
- What must the sponsor finance, and are there distinct, independent Norwegian research questions that could qualify for other funding?
- What would justify stopping — and, if the case is worth pursuing, who does what next?
Lived experience should be able to do more than testify.
Human Autonomy Study began with a question I could not separate from my own recovery: how is human autonomy rebuilt when capacity is low?
I want lived experience to help identify problems, define outcomes and generate better research questions — not only become a story about suffering after the important decisions have already been made.
That does not make my recovery evidence for a medicine. It gives me a reason to ask more of what comes next. Scientific conclusions still have to be earned through research.
Shame and taboo should not determine which questions we are willing to investigate. Nor should they determine how much ambition we have for the lives people can rebuild.
A concrete proposal deserves a concrete answer.
To researchers: what would make this a worthwhile study, and what would make it a poor one? To the developer: what information and commitments would a Norwegian assessment require? To those responsible for research policy: how do your stated ambitions become practical opportunities in addiction treatment?
I invite journalists to examine both the proposal and the wider priorities: follow the documentation, ask independent experts, and test the assumptions. People with lived experience, families and professional organisations should help define what better outcomes would mean.
A reasoned no is an answer. A yes should identify a viable next step. The immediate goal is not an endorsement, but a named contact and a defined task that moves the assessment forward.
I survived. I want that to become more than the ending of my own story.
I am not asking Norway to believe in DMX-1001. I am asking Norway to help determine whether it works for alcohol use disorder, and whether its benefits outweigh its risks.
PRIMARY SOURCES
- Norwegian Government — clinical-research plan and targets, 23 March 2026
- Norwegian Government — Meld. St. 5 (2024–2025), section 11.1: societal costs and undertreatment
- Norwegian Institute of Public Health — Causes of death in Norway 2024, p. 55: alcohol-induced deaths
- DemeRx — Science & Pipeline: DMX-1001 / AUD
- DemeRx — company report on Phase 1 completion, 6 January 2026
- DemeRx — company report on FDA acceptance of IND, 22 April 2026
- NorTrials — coordinating unit and national feasibility gateway
- ClinicalTrials.gov — NCT06480981, study registration